Diphenylpyraline
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Diphenylpyraline: From Allergic Rhinitis to Nasal Cavity Disease
One-Sentence Summary
Diphenylpyraline is a first-generation antihistamine. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently 0 clinical trials and 0 publications supporting this prediction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis (relation recorded in the knowledge graph; the Canadian licence records contain no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9915 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Number of approvals | 2 licences (both single-ingredient products) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, diphenylpyraline belongs to the first-generation H1-antihistamine class. These drugs block histamine H1 receptors and have anticholinergic effects that can reduce nasal secretions. This class pharmacology has not been verified from the data compiled for this report.
Allergic rhinitis, vasomotor rhinitis, pharyngitis and the common cold are mostly nasal or upper airway conditions. “Nasal cavity disease” is a broad parent category. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It does not point to a new indication or a distinct disease subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00299561 | CREO-RECTAL ADULTES/ADULTS | Not specified | Not specified |
| 00299596 | CREO-RECTAL ENFANTS/CHILDREN | Not specified | Not specified |
Both licences are valid. The product names suggest a rectal route, which may not suit nasal indications. The compiled data does not confirm the route, and route compatibility has not been assessed.
Safety Considerations
- Conditions recorded as contraindications in the knowledge graph (these come from graph relations, not label text): hypertensive disorder, hypertension, peptic ulcer disease, benign prostatic hyperplasia, ocular hypertension, angle-closure glaucoma, closed-angle glaucoma, hyperthyroidism, Graves disease, thyrotoxicosis, bladder neck obstruction.
- Drug Interactions: The interaction query returned no records.
Please refer to the package insert for label warnings and contraindications, as these were not available in the compiled data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. No trials or publications address this disease, so the evidence level is L5. “Nasal cavity disease” is a broad category that overlaps with conditions already recorded for the drug, so it is not a clearly new indication.
To proceed, the following is needed:
- Health Canada package insert warnings, contraindications and approved indication text (a blocking gap for safety screening)
- Mechanism of action data
- A more specific disease target than the broad “nasal cavity disease” category
- Confirmation of the dosage forms and routes of the marketed products, and their compatibility with nasal use
- Any clinical or literature evidence that directly studies the predicted disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.